Stryker reported Q4 EPS of $4.47, beating Zacks Consensus estimate of $4.40 and delivered double-digit organic revenue growth driven by strong adoption of its Mako robotic-arm platform. The company also raised its full-year profit forecast on robust implant and medical device sales, highlighting sustained demand across its surgical orthopedics business.